On November 05, 2026, the Stochastic Oscillator for NRXP moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 65 instances where the indicator left the oversold zone. In 54 of the 65 cases the stock moved higher in the following days. This puts the odds of a move higher at over 83%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NRXP's RSI Indicator exited the oversold zone, 32 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for NRXP just turned positive on November 06, 2026. Looking at past instances where NRXP's MACD turned positive, the stock continued to rise in 32 of 39 cases over the following month. The odds of a continued upward trend are 82%.
Following a +14.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXP advanced for three days, in 191 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
NRXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NRXP as a result. In 75 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 50-day moving average for NRXP moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NRXP entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NRXP's P/B Ratio (-606.141) is very low in comparison to the industry average of (3.498). P/E Ratio (-4.667) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (29.851) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. NRXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TTRX advanced for three days, in 55 of 61 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 9 of 12 cases where TTRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for TTRX just turned positive on November 11, 2026. Looking at past instances where TTRX's MACD turned positive, the stock continued to rise in 7 of 8 cases over the following month. The odds of a continued upward trend are 88%.
TTRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TTRX as a result. In 15 of 18 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
TTRX moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TTRX crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 1 of 1 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TTRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for TTRX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TTRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TTRX's P/B Ratio (419.116) is very high in comparison to the industry average of (3.498). P/E Ratio (-33.435) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TTRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NRXP | ||
|---|---|---|
OUTLOOK RATING 1..100 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 76 | |
P/E GROWTH RATING 1..100 | 12 | |
SEASONALITY SCORE 1..100 | 20 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| NRXP | TTRX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 78% | N/A |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 88% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Advances ODDS (%) | 8 days ago 82% | 1 day ago 90% |
| Declines ODDS (%) | 10 days ago 89% | 9 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 79% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NRXP’s FA Score shows that 2 FA rating(s) are green while TTRX’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NRXP’s TA Score shows that 5 TA indicator(s) are bullish while TTRX’s TA Score has 3 bullish TA indicator(s).
NRXP (@Biotechnology) experienced а +5.36% price change this week, while TTRX (@Biotechnology) price change was +4.31% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
NRXP is expected to report earnings on Nov 13, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, NRXP has been closely correlated with TAOX. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if NRXP jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To NRXP | 1D Price Change % | ||
|---|---|---|---|---|
| NRXP | 100% | +3.39% | ||
| TAOX - NRXP | 84% Closely correlated | -1.55% | ||
| ALLR - NRXP | 81% Closely correlated | +2.76% | ||
| PALI - NRXP | 74% Closely correlated | +3.54% | ||
| COYA - NRXP | 39% Loosely correlated | +1.58% | ||
| BCYC - NRXP | 35% Loosely correlated | N/A | ||
More | ||||
A.I.dvisor tells us that TTRX and ROIV have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TTRX and ROIV's prices will move in lockstep.
| Ticker / NAME | Correlation To TTRX | 1D Price Change % | ||
|---|---|---|---|---|
| TTRX | 100% | +6.55% | ||
| ROIV - TTRX | 28% Poorly correlated | +1.60% | ||
| NRXP - TTRX | 25% Poorly correlated | +3.39% | ||
| INTS - TTRX | 24% Poorly correlated | +6.15% | ||
| PHVS - TTRX | 24% Poorly correlated | +0.56% | ||
| ABEO - TTRX | 22% Poorly correlated | -6.31% | ||
More | ||||